Anuh Pharma Limited has informed the Exchange regarding 'Adoption of Memorandum of Association (MOA) and Articles of Association (AOA) as per Companies Act, 2013.'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anuh Pharma Limited reported FY2025-26 results with revenue from operations growing 16.6% YoY to Rs. 77,165.74 Lakhs. However, profit after tax declined 13.3% to Rs. 4,104.61 Lakhs, while EBITDA margin compressed from 10.64% to 8.56%. Operating cash flow turned negative at Rs. -301.16 Lakhs (vs +Rs. 3,712.47 Lakhs in prior year). Inventories nearly doubled to Rs. 14,775.50 Lakhs. The Board recommended a dividend of Rs. 1.50 per share (30% payout). Nine promoter group members (holding 0.95% shares) sought reclassification to public category. The company also approved new MOA/AOA, appointed new internal auditors (RMJ & Associates LLP), and a new GM-Quality.
Despite revenue growth, the sharp decline in profitability, margin compression, and negative operating cash flow signal operational stress. Shareholders may face pressure on returns despite the dividend recommendation.